---
title: "Blood methylation profile stratifies 10-year risk for 21 common diseases"
id: "medrxiv-20-one-blood-methylation-profile-stratifies-ten-year-risk-across-21-common-diseases"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-20-one-blood-methylation-profile-stratifies-ten-year-risk-across-21-common-diseases"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.18.26368164v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Blood methylation profile stratifies 10-year risk for 21 common diseases
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-20-one-blood-methylation-profile-stratifies-ten-year-risk-across-21-common-diseases
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.18.26368164v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators combined DNA methylation data from Generation Scotland and the Mass General Brigham Biobank to develop risk scores for 21 common diseases. - The analysis included 12,785 adults; the authors used technically reproducible probes, null-calibrated feature selection and ten-year survival models. - Models were evaluated in a single holdout set that was not used for feature selection, model fitting, or tuning. - Eight disease-specific **methylation risk scores** reached a holdout C-index ≥ 0.80: chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, heart failure, type 2 diabetes, interstitial lung disease, dementia and fatty liver disease. - For five diseases with at least 50 events, adjusted hazard ratios per standard deviation ranged from 2.6 to 4.1; the highest-risk tertile contained 73–90% of ten-year events. - Panel CpG sites were enriched for pathways in cytokine signalling, innate immune sensing and sterol metabolism. - When compared with published polygenic and methylation scores, these eight top-tier scores exceeded many published scores alone and, for seven of eight diseases, exceeded published polygenic-plus-clinical models (type 2 diabetes was the exception). - The source did not report detailed probe lists, exact model coefficients, or the full set of feature-selection parameters in the abstract; those details may be in supplementary files but are not in the source body provided here. - Data access is restricted by cohort consent and governance; Generation Scotland and MGB require formal requests for data sharing under their access procedures. - Multiple authors are employees or advisors to TruDiagnostic, and competing interests are disclosed in the source.
## Clinical Analysis & Structured Key Points
One blood methylation profile stratifies ten-year risk across 21 common diseases | medRxiv Skip to main content One blood methylation profile stratifies ten-year risk across 21 common diseases Kirsten Blythe Seale , Sayf Hassouneh , Laura Balagué-Dobón , Max Melnikas , Andrea Aparicio , Tao Guo , Kerry L Ivey , Jessica A. Lasky-Su , Anne Richmond , Riccardo Marioni , Mike Mallin , Varun B Dwaraka , Natàlia Carreras-Gallo , Ryan Smith doi: https://doi.org/10.64898/2026.11.18.26368164 Kirsten Blythe Seale 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sayf Hassouneh 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Laura Balagué-Dobón 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Max Melnikas 2 Harvard Medical School and Brigham and Womens Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrea Aparicio 2 Harvard Medical School and Brigham and Womens Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tao Guo 2 Harvard Medical School and Brigham and Womens Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kerry L Ivey 2 Harvard Medical School and Brigham and Womens Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jessica A. Lasky-Su 2 Harvard Medical School and Brigham and Womens Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anne Richmond 3 The University of Edinburgh Find this author on Google Scholar Find this author on PubMed Search for this author on this site Riccardo Marioni 3 The University of Edinburgh Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mike Mallin 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Varun B Dwaraka 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Natàlia Carreras-Gallo 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ryan Smith 1 TruDiagnostic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: ryan{at}trudiagnostic.com Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Blood DNA methylation offers a dynamic readout of inherited and acquired influences on health, creating an opportunity for risk prediction beyond polygenic scores, which are fixed at conception and have yet to demonstrate broad clinical utility. As such, we aimed to develop methylation risk scores for 21 common diseases in 12,785 adults from Generation Scotland and the Mass General Brigham Biobank, combining technically reproducible probes, null-calibrated feature selection and ten-year survival models, with evaluation in a single holdout that was not used for feature selection, model fitting or tuning. The methylation risk scores for eight diseases reached a holdout C-index of at least 0.80: chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, heart failure and type 2 diabetes with at least 50 events each, and interstitial lung disease, dementia and fatty liver disease with fewer. For the five scores with at least 50 events, adjusted hazard ratios per standard deviation ranged from 2.6 to 4.1, with the highest risk tertile containing 73 to 90% of the ten-year events. Panel CpGs were enriched for cytokine signalling, innate immune sensing and sterol metabolism. Against reported values, the eight top-tier methylation risk scores exceed published polygenic and methylation scores alone, and exceed published polygenic and methylation scores that include clinical covariates for seven of the eight diseases (the exception is type 2 diabetes, where our AUC of 0.865 without clinical risk factors is close to a methylation-plus-risk-factor model at 0.872, and our C-index of 0.809 is lower than the C-index for a polygenic-plus-risk-factor at 0.85). These results indicate that a single blood methylation profile can rank ten-year risk for several common diseases at a level that compares favourably with published genetic and methylation scores. Competing Interest Statement K.B.S., N.C.-G., L.B.-D., S.H., M.Ma., V.D. and R.S. are all employees of TruDiagnostic. J.L.S. is a scientific advisor to TruDiagnostic, Infinite Epigenetics and Antipode. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was a secondary analysis of existing, de-identified data from two cohorts and involved no new participant recruitment, and was conducted in accordance with all applicable ethical guidelines and regulations. For MGB, ethical approval was obtained by the Mass General Brigham Institutional Review Board (protocol 2026P001153), and informed consent was obtained from all participants prior to their inclusion in the study. Data were anonymized to protect participant privacy, and confidentiality was strictly maintained throughout the study. All human subject research adhered to the principles outlined in the Declaration of Helsinki, ensuring respect for individuals, beneficence, and justice. All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 25/ES/0013), providing ethical approval for a wide range of uses within medical research. Written informed consent was obtained from all participants in GS:SFHS. This study was performed in accordance with the Helsinki declaration. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data from GS and the MGB Biobank cannot be shared publicly because of participant consent and data access agreements. According to the terms of consent for Generation Scotland participants, access to data must be reviewed by the Generation Scotland Access Committee. Access requests can be made through the researcher portal (https://gsaccess.igc.ed.ac.uk) and normally take up to six weeks for approval. Further information can be found on the Generation Scotland website: https://genscot.ed.ac.uk/for-researchers/access. MGB data can be shared for research purposes upon request via a Data Use Agreement by email request to Jessica Lasky-Su (rejas{at}channing.harvard.edu). Funder Information Declared National Heart, Lung, and Blood Institute (NHLBI) , R01HL155742 Scottish Funding Council , HR03006 Scottish Government Health Directorates , CZD/16/6 Wellcome Trust , 104036/Z/14/Z , 220857/Z/20/Z , 216767/Z/19/Z Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Back to top Previous Next Posted November 20, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following One blood methylation profile stratifies ten-year risk across 21 common diseases Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share One blood methylation profile stratifies ten-year risk across 21 common diseases Kirsten Blythe Seale , Sayf Hassouneh , Laura Balagué-Dobón , Max Melnikas , Andrea Aparicio , Tao Guo , Kerry L Ivey , Jessica A. Lasky-Su , Anne Richmond , Riccardo Marioni , Mike Mallin , Varun B Dwaraka , Natàlia Carreras-Gallo , Ryan Smith medRxiv 2026.11.18.26368164; doi: https://doi.org/10.64898/2026.11.18.26368164 Share This Article: Copy Citation Tools One blood methylation profile stratifies ten-year risk across 21 common diseases Kirsten Blythe Seale , Sayf Hassouneh , Laura Balagué-Dobón , Max Melnikas , Andrea Aparicio , Tao Guo , Kerry L Ivey , Jessica A. Lasky-Su , Anne Richmond , Riccardo Marioni , Mike Mallin , Varun B Dwaraka , Natàlia Carreras-Gallo , Ryan Smith medRxiv 2026.11.18.26368164; doi: https://doi.org/10.64898/2026.11.18.26368164 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (928) Anesthesia (355) Cardiovascular Medicine (5059) Dentistry and Oral Medicine (496) Dermatology (432) Emergency Medicine (681) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1703) Epidemiology (16352) Forensic Medicine (37) Gastroenterology (1249) Genetic and Genomic Medicine (7333) Geriatric Medicine (761) Health Economics (1101) Health Informatics (5350) Health Policy (1480) Health Systems and Quality Improvement (1847) Hematology (604) HIV/AIDS (1389) Infectious Diseases (except HIV/AIDS) (16537) Intensive Care and Critical Care Medicine (1210) Medical Education (702) Medical Ethics (157) Nephrology (757) Neurology (7664) Nursing (380) Nutrition (1144) Obstetrics and Gynecology (1308) Occupational and Environmental Health (1046) Oncology (3769) Ophthalmology (1105) Orthopedics (414) Otolaryngology (474) Pain Medicine (508) Palliative Medicine (144) Pathology (727) Pediatrics (1877) Pharmacology and Therapeutics (759) Primary Care Research (793) Psychiatry and Clinical Psychology (6186) Public and Global Health (10051) Radiology and Imaging (2562) Rehabilitation Medicine and Physical Therapy (1540) Respiratory Medicine (1280) Rheumatology (666) Sexual and Reproductive Health (814) Sports Medicine (601) Surgery (809) Toxicology (109) Transplantation (321) Urology (309)
## Related Clinical Research

- [Embolic Stroke and DOAC Failure in Libman-Sacks Endocarditis with Antiphospholipid Syndrome](https://medichelpline.com/clinical-feed/pubmed-43058350.md) (DOI: 10.1007/s00296-026-06331-w)
- [Finerenone Slows eGFR Decline in Chronic Kidney Disease Patients Without Diabetes](https://medichelpline.com/clinical-feed/pubmed-42246672.md) (DOI: 10.1056/NEJMoa2604625)
- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)
- [Optimizing Basal Insulin Therapy for Type 2 Diabetes: The Role of Once-Weekly Insulins](https://medichelpline.com/clinical-feed/endocrine-news-0-advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in.md)
- [Chronic Kidney Disease Prevalence and Management in Irish Primary Care (CRADLE EHR Study)](https://medichelpline.com/clinical-feed/medrxiv-1-prevalence-and-management-of-chronic-kidney-disease-in-irish-primary-care.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.